Current Molecularly Targeting Therapies in NSCLC and Melanoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Traditional cancer treatments like surgery, radiation, and chemotherapy have significant side effects and limited efficacy in advanced or metastatic cancers.
• Biomarkers overexpressed in cancer, crucial for cell growth and survival, are emerging targets for novel molecular therapies.
• Tyrosine kinase inhibitors and monoclonal antibodies represent promising targeted therapies with potentially greater efficacy and reduced toxicity.

Purpose of the Study:

• To review the clinical status of targeted therapies, specifically tyrosine kinase inhibitors and monoclonal antibodies.
• To discuss prevalent biomarkers targeted in non-small cell lung cancer (NSCLC) and melanoma.
• To highlight the challenge of drug resistance and the focus on understanding its mechanisms.

Main Methods:

• Literature review of clinical trials and research studies.
• Analysis of targeted therapies (tyrosine kinase inhibitors, monoclonal antibodies) against cancer biomarkers.
• Focus on non-small cell lung cancer (NSCLC) and melanoma patient populations.

Main Results:

• Targeted therapies show promise but face limitations due to acquired drug resistance.
• Understanding resistance mechanisms is critical for optimizing treatment strategies.
• Several biomarkers are under investigation for targeted therapy in NSCLC and melanoma.

Conclusions:

• Targeted therapies offer a more precise approach to cancer treatment compared to traditional methods.
• Overcoming drug resistance is a key challenge for the long-term success of these therapies.
• Continued research into biomarkers and resistance mechanisms is essential for advancing cancer care in NSCLC and melanoma.